

PHARMACEUTICAL 2022

Sonoma Pharmaceuticals Inc. Rank 327 of 466









PHARMACEUTICAL 2022



Sonoma Pharmaceuticals Inc. Rank 327 of 466

The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 118% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 43%, being 35% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	12,983
Cost of Goods Sold	12,070
Intangible Assets	0
Liabilities, Current	4,078
Liabilities, Non-Current	1,839
Other Assets	1,644
Other Compr. Net Income	0
Other Expenses	725
Other Liabilities	3,707
Other Net Income	224
Other Revenues	18,629
Property and Equipment	360
Research and Development	555
Selling, General and Administrative Expense	9,453

Output Variable	Value in 1000 USD
Assets	14,987
Liabilities	9,624
Expenses	22,803
Revenues	18,629
Stockholders Equity	5,363
Net Income	-3,950
Comprehensive Net Income	-3,950
Economic Capital Ratio	43%

